FTC Approves Amgen's Acquisition of Horizon

The US Federal Trade Commission (FTC) wants to clear the takeover of Irish biotech company Horizon Therapeutics by pharmaceutical group Amgen. Following concessions by Amgen, the authority is dropping its earlier objections to the $27.8 billion purchase, the FTC announced last Friday.

In May, the FTC had opposed the acquisition, arguing that Horizon had a monopoly position with its drugs in the US in the fight against certain diseases.

But the FTC attaches conditions to its approval: Amgen may not bundle any of its products with Horizon's Tepezza or Krystexxa, nor may it use rebates or contract terms to disadvantage competing products. In addition, Amgen may acquire potential competing products to Horizon drugs only with the FTC's permission.

As a result of the agreement with the FTC, Amgen and Horizon expect to jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the US District Court for the Northern District of Illinois, and that the companies will quickly seek the final approvals required under Irish law to close the acquisition.

Amgen and Horizon anticipate being able to close the acquisition in early fourth-quarter 2023 and look forward to the opportunity to serve patients around the world suffering from rare diseases.

Source: Amgen
Source: Amgen

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.